ENPP2 and idiopathic pulmonary fibrosis: This is why the ATX inhibitor, GLPG1690 [24], and an LPA1 receptor antagonist (BMS986020) [25], have attenuated idiopathic pulmonary fibrosis in Phase 2a clinical trials.